Publications by authors named "P R Beatty"

Insight into human physiology is key to maintaining diver safety in underwater operational environments. Numerous hazardous physiological phenomena can occur during the descent, the time at depth, the ascent, and the hours after a dive that can have enduring consequences. While safety measures and strict adherence to dive protocols make these events uncommon, diving disorders still occur, often with insufficient understanding of the factors that triggered the event.

View Article and Find Full Text PDF
Article Synopsis
  • - Flaviviruses are a group of viruses that cause serious diseases in humans, including dengue and Zika, and rely on a protein called NS1 for replication and disease severity.
  • - NS1 is secreted from infected cells and contributes to endothelial dysfunction, which affects blood vessel permeability and may facilitate the spread of the virus in the body.
  • - Research demonstrates that NS1 aids in the virus's ability to cross endothelial barriers and boosts the infectivity of specific target cells, indicating its crucial role in virus dissemination and its impact on disease progression.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between yellow fever virus (YFV) nonstructural protein 1 (NS1) and disease severity in yellow fever (YF) patients, highlighting how increased NS1 levels correlate with vascular dysfunction and severe clinical outcomes.
  • Researchers analyzed serum samples from patients with severe and non-severe YF cases, finding higher levels of NS1 and syndecan-1 (a vascular leak marker) in severe cases.
  • Results indicate that YFV NS1 contributes to endothelial dysfunction by inducing shedding of syndecan-1, suggesting these serum markers could be used for diagnosing and predicting disease severity in YF.
View Article and Find Full Text PDF

Genetic medicines show promise for treating various diseases, yet clinical success has been limited by tolerability, scalability, and immunogenicity issues of current delivery platforms. To overcome these, we developed a proteolipid vehicle (PLV) by combining features from viral and non-viral approaches. PLVs incorporate fusion-associated small transmembrane (FAST) proteins isolated from fusogenic orthoreoviruses into a well-tolerated lipid formulation, using scalable microfluidic mixing.

View Article and Find Full Text PDF